Basic Ketone Engine and Booster Glucose Engine for Energy Production
DOI:
https://doi.org/10.17140/DROJ-2-125Keywords:
Ketone β-hydroxy butyrate, TCA cycle, Histon Gestational diabetes, Fast Endocrine, Metabolism Pharmacology.Abstract
Recently, hyperketonemia induced by fasting or ketogenic diet calls attention because of the possibilities for various clinical applications. Animal species comparisons and biochemical data show that all fetuses can develop by using ketogenic energy through a pathway which seems to have been maintained. We hypothesized that 3-β-hydroxybutyrate (β-HB) could be the fuel for the basic engine that produces energy in all terrestrial species. However, ATP production from glucose-pyruvic acid pathway seems to be added as a dominant system in human. We hypothesize the establishment of TCA cycle in mitochondria and enough oxygen supply since two billion years ago would be the key events to promote this change. The efficacy of ATP production from β-oxidation product is 10 ATP molecules, while it is 12.5 molecules from pyruvic acid. So, evolution should select glucose burning system as a booster engine for energy production. The liver and kidney are major ketone producing organs which contain abundant glycogen particles. So, a close relationship between ketone and glucose burning system may be present. This explains why certain level of glucose is steadily maintained even in the hyperketogenic state. Ketogenic diets efficiently treat with gestational diabetes. Placenta is the ketogenic tissue which reflects high concentration of ketones in umbilical cord blood. In addition to the role of energy source, β-HB shows various pharmacological effects on disease prevention, such as cardiovascular disease, Alzheimer’s disease, epilepsy, etc. Inhibition
of histone deacetylase, stimulation of FOXO, resistance to oxidative stress, protection of mitochondria, stimulation of adiponectin release, suppression of inflammasome, etc. are included. The contribution of intestinal microbiota to ketone body production should open a new field of medicine. Altogether, the above data suggest that longer-term human studies are necessary to exclude risks of unbalanced diet and to confirm the best combination of fuels for energy production, disease prevention and medical treatment.
References
Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009; 32(7): 1335-1343. doi: 10.2337/dc09-9032
Cahill GF Jr. Fuel metabolism in starvation. Ann Rev Nutr. 2006; 26: 1-22. doi: 10.1146/annurev.nutr.26.061505.111258
Cahill GF Jr, Veechi RL. Ketoacids? Good medicine? Trans Am Clin Climatol Assoc. 2003; 114: 149-163.
Laffel L. Ketone bodies: A review of physiology, patho-physiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999; 15(6): 412-426. doi: 10.1002/(SICI)1520- 7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8
Hirakawa A, Watanabe S, Tanaka S. Koda’s fasting therapy: Energy balance and intestinal bacterial flora. Adv Food Technol Nutr Sci Open J. 2015; 1(5): 112-123. doi: 10.17140/ AFTNSOJ-1-120
Blazques C, Woods A, de Ceballos ML, Carling D, Guzman M. The AMP-activated protein kinase is involved in the regulation of ketone body production by astrocytes. J Neurochem. 1999; 73(4): 1674-1682. doi: 10.1046/j.1471-4159.1999.731674.x
Koda M. Science of the fasting therapy. Practical improve-ment of constitution. Osaka, Japan: Shun-ju-sha; 1980.
NIH, The National Institute of Diabetes and Digestive and Kidney Diseases. Gestational diabetes. 2014. Web site. https://www.niddk.nih.gov/health-information/diabetes/types/ gestational. Accessed June 28, 2016
Ogushi Y, Hanaki Y, Muneta T, Douya H, Yamauchi T. Zero saccharide diet research group. Japan Society for Lipid Nutrition. 2010; 19(1): 53-58.
Shambaugh GE 3rd. Ketone body metabolism in the mother and fetus. Fed Proc. 1985; 44(7): 2347-2351.
Watanabe S. People’s physician. Angel for mothers. Muneta Maternal Clinic. Clin Funct Nutr. 2016; 8(4): 159-162.
Krempaský M, Maskaľová I, Bujňák L, Vajda V. Ketone bodies in blood of dairy cows: Prevalence and monitoring of subclinical ketosis. Acta Vet Brno. 2014, 83: 411-416. doi: 10.2754/avb201483040411
Kostiuk MA, Keller BO, Berthiaume LG. Palmitoylation of ketogenic enzyme HMGCS2 enhances its interation with PPAR alpha and transcription at the Hmgcs 2 PPRE. FASEB J. 2010; 24(6): 1914-1924. doi: 10.1096/fj.09-149765
Hegardt FG. Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: A control enzyme in ketogenesis. Biochem J. 1999; 338(Pt3): 569-582. doi: 10.1042/bj3380569
Urich K. Ketone body formation and degradation. In: Comparative Animal Biochemistry. Berlin, Germany: Springer-Verlag; 1993: 579-580.
Partsalaki I, Karvela A, Spiliotis BE. Metabolic impact of a ketogenic diet compared to a hypocaloric diet in obese children and adolescents. J Pediatr Endocrinol Metab. 2012; 25(7-8): 697-704. Web site. http://www.degruyter.com/view/j/ jpem.2012.25.issue-7-8/jpem-2012-0131/jpem-2012-0131.xml. Accessed June 28, 2016
Bender DA, Mayer PA. Glycolysis & the oxidation of pyruvate. In: Murray RK, Bender AD, Botham KM, et al, eds. Harper’s Illustrated Biochemistry. 29th ed. Lange, NY, USA: McGraw Hill Professional; 2012: 170-177.
Wilder RM, Winter MD. The threshold of ketogenesis. J Biol Chem. 1922; 52: 393-401. Web site. http://www.jbc.org/ content/52/2/393.short. Accessed June 28, 2016
Kossoff EH. Zupec-Kanici BA, Amask PE, et al. Optimal clinical management of children receiving the ketogenic diet: Recommendations of the International Ketogenic Diet Study Group. Epilepsia. 2009; 50(2): 304-317. doi: 10.1111/j.1528- 1167.2008.01765.x
Cervenka MC, Henry BJ, Felton EA, Patton K, Kossoff EH. Establishing an adult epilepsy diet center: Experience, efficacy and challenges. Epilepsy Behav. 2016; 58: 61-68. doi: 10.1016/j. yebeh.2016.02
Mosek A, Natour H, Neufeld MY, Shiff Y, Vaisman N. Ketogenic diet treatment in adults with refractory epilepsy: A prospective pilot study. Seizur. 2009; 18(1): 30-33. doi: 10.1016/j.seizure.2008.06.001
Evangeliou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. J Child Neurol. 2003; 18(2): 113-118. doi: 10.1177/08830738030180020501
Chen Y, Du J, Zhao YT, et al. Histone deacetylase (HDAC) in hibition improves myocardial function and prevents cardiac remodeling in diabetic mice. Cardiovasc Diabetol. 2015; 14: 1-99. doi: 101186/512933-015-0262-8
Zou Z, Sasaguri S, Rajesh KG, Suzuki R. dl-3- Hydroxybutyrate administration prevents myocardial damage after coronary occlusion in rat hearts. Am J Physiol Heart Circ Physiol. 2002; 283(5): H1968-H1974. doi: 10.1152/ ajpheart.00250.2002
Honda H, Sasaki K, Hamasaki H, et al. Trends in autopsy-verified dementia prevalence over 29 years of the Hisayama study. Neuropathology. 2016; 36(4): 383-387. doi: 10.1111/ neup.12298
Matsuzaki T1, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama study. Neurology. 2010; 75(9): 764-770. doi: 10.1212/ WNL.0b013e3181eee25f
Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: Ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids. 2004; 70(3): 309-319. doi: 10.1016/j.plefa.2003.09.007
Xu K, Sun X, Eroku BO, Tsipis CP, Puchowicz MA, LaManna JC. Diet-induced ketosis improves cognitive performance in aged rats. Adv Exp Med Biol. 2010; 662: 71-75. doi: 10.1007/978-1-4419-1241-1_9
Mohamed HE, El-Swefy SE, Rashed LA, Abd El-Latif SK. Biochemical effect of a ketogenic diet on the brains of obese adult rats. J Clin Neurosci. 2010; 17(7): 899-904. doi: 10.1016/j. jocn.2009.11.005
Newman JC, Verdin E. β-hydroxybutyrate: much more than a metabolite. Diabetes Res Clin Practice. 2014; 106(2): 173- 181. doi: 10.1016/j.diabres.2014.08.009
Arzheimer’s association. Capric acid. Web site. http:// www.alz.org/alzheimers_disease_alternative_treatments.asp. Accessed June 28, 2016
Nebeling LC, Miraldi F, Shurin SB, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: Two case reports. J Am Coll Nutr. 1995; 14(2): 202-208. doi: 10.1080/07315724.1995.10718495
Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013; 339(6116): 211-214. doi: 10.1126/science.1227166
Gräff J, Tsai LH. The potential of HDAC inhibitors as cognitive enhancers. Annu Rev Pharmacol Toxicol. 2013; 53: 311-330. doi: 10.1146/annurev-pharmtox-011112-140216
Chen Y, Du J, Zhao YT, et al. Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice. Cardiovasc Diabetol. 2015; 14: 99. doi: 10.1186/s12933-015-0262-8
Aune SE, Herr DJ, Mani SK, Menick DR. Selective inhibition of class I but not class IIb histone deacetylases exerts cardiac protection from ischemia reperfusion. J Mol Cell Cardiol. 2014; 72: 138-145. doi: 10.1016/j.yjmcc.2014.03.005
Blakeslee WW, Wysoczynski CL, Fritz KS, Nyborg JK, Churchill ME, McKinsey TA. Class I HDAC inhibition stimulates cardiac protein SUMOylation through a post-translational mechanism. Cell Signal. 2014; 26(12): 2912-2220. doi: 10.1016/j.cellsig.2014.09.005
Edwards C, Canfield J, Copes N, Rehan M, Lipps D, Bradshaw PC. D-beta-hydroxybutyrate extends lifespan in C. elegans. Aging (Albany NY). 2014; 6(8): 621-644. doi: 10.18632/ aging.100683
Zhang J, Cao Q, Li S, et al. 3-Hydroxybutyrate methyl ester as a potential drug against Alzheimer’s disease via mitochondria protection mechanism. Biomaterials. 2013; 34(30): 7552-7562. doi: 10.1016/j.biomaterials.2013.06.043
Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RL. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am J Physiol Endocrinol Metab. 2009; 296(3): E549-58. doi: 10.1152/ajpendo.91004.200841
Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015; 21(3): 263-269. doi: 10.1038/nm.3804
Poff AM, Ari C, Arnold P, Seyfried TN, D’Agostine DP. Ketone supplementation decreases tumor cell vaiability and prolongs survival of mice with metastatic cancer. Int J Cancer. 2014; 135(7): 1711-1720. doi: 10.1002/ijc.28809
Shukla SK, Gebegiworgis T, Purohit V, et al. Metabolic reprograming induced by ketone bodies diminishes pancreatic cachexia. Cancer Metab. 2014; 2: 18. doi: 10.1186/2049-3002- 2-18
Oleksyszyn J. The complete control of glucose level utilizing the composition of ketoenic diet with the gluconeogenesis inhibitor, the anti-diabetic drug methormin, as a potential anti-cancer therapy. Med Hypotheses. 2011; 77(2): 171-173. doi: 10.1016/j.mehy.2011.04.001
Maurer GD, Brucker DP, Bahr O, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: A rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011; 11: 315. doi: 10.1186/1471-2407-11-315
Bonuccelli G, TsirigosA, Whitaker-Menezes D, et al. Ketones and lactate “fuel” tumor growth and metastasis: Evidence that cancer cells use oxidative mitochondrial metabolism. Cell cycle. 2010; 9(17): 3506-3514. doi: 10.4161/cc.9.17.12731
Adbelwahab MG, Fenton KE, Preul MC, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One. 2012; 7(5): e36197. doi: 10.1371/journal.pone.0036197
Guo LS, Li HX, Li CY, et al. Synergistic antitumor activ-ity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signal-ing pathways. Pharmazie. 2015; 70(2): 117-122. doi: 10.1691/ ph.2015.4535
Watanabe S. Cardiovascular risk of high protein diet. Clin Funct Nutr. 2012; 4(4): 186-191.
Hirakawa A, Melby MK, Watanabe S. Comprehensive food labeling for obesity control. Adv Obes Weight Manag Control. 2016; 4(3): 00088. doi: 10.15406/aowmc.2016.04.00088
Moorkoth D, Nampoothiri KM. Production and characteriza-tion of poly (3-hydroxy butyrate-co-3 hydroxyvalerate) (PHBV) by a novel halotolerant mangrove isolate. Bioresour Technol. 2016; 201: 253-260. doi: 10.1016/j.biortech.2015.11.046
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Diabetes Research (DR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
